Oragenics Inc Dossier
Qualitative Analysis
Business overview
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biopharmaceutical company focused on the research and development of brain-targeted, nasally delivered pharmaceutical therapies for neurological conditions. The company's proprietary intranasal drug delivery platform is designed to enable rapid, non-invasive delivery of therapeutic compounds directly to the brain via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. Its lead product candidate is ONP-002, a fully synthetic, lipophilic neurosteroid being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury (mTBI). Concussion represents a massive global unmet medical need with an estimated 69 million individuals affected annually and no FDA-approved pharmacological treatments currently available.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead candidate ONP-002, a first-in-class intranasal neurosteroid, through a 40-patient Phase IIa clinical trial in Australia for the treatment of concussion and mild traumatic brain injury (mTBI).
Expected impact: Establish clinical proof-of-concept and safety profile to support U.S. regulatory filings and transition to Phase IIb trials.
Partnering with DUCK FLATS Pharma to align the Australian Phase IIa clinical trial design with U.S. FDA requirements and prepare the regulatory strategy for U.S.-based clinical development.
Expected impact: De-risk the U.S. regulatory pathway and secure FDA guidance on the clinical development path before initiating U.S. trials.
Collaborating with Receptor.AI to utilize advanced artificial intelligence modeling to identify optimal receptor binding profiles for compounds acquired in 2023, expanding the pipeline beyond ONP-002.
Expected impact: Transition Oragenics from a single-asset company to a diversified neurological therapeutics developer with multiple preclinical candidates.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Allows Oragenics to license CardioDialysis™, an extracorporeal blood purification technology, for Traumatic Brain Injury (TBI) and chronic neurodegenerative diseases. This pairs with ONP-002 to target TBI-induced inflammation on both sides of the blood-brain barrier.
Terms: Oragenics expects to issue 3,250,000 shares of a new class of restricted preferred stock to Sigyn (convertible 1-to-1 into common stock) and pay a 3% royalty on net sales of the licensed technology for six years post-FDA market clearance.
Engaged as the U.S. IND readiness partner to support FDA-facing preparation, nonclinical strategy, and clinical trial design for the ONP-002 concussion program.
Terms: Terms of the engagement were not publicly disclosed.
Utilizes computational models to analyze molecular structures and predict therapeutic receptor targets for Oragenics' expanded CNS pipeline.
Terms: Terms of the collaboration were not publicly disclosed.